In The Eye Of Analysts: HollyFrontier Corporation (HFC), Sarepta Therapeutics, Inc. (SRPT) – The RNS Daily

This post was originally published on this site

HollyFrontier Corporation (NYSE:HFC) jumped by 0.87% on Thursday and this got the market excited. This price movement has led to the HFC stock receiving more attention and has become one to watch out for. The shares dropped by -37.37% or -$31.12 from its last recorded high of $83.28 which it attained on April 06 to close at $52.16 per share. Over the past 52 weeks, the shares of HollyFrontier Corporation has been trading as low as $44.7 before witnessing a massive surge by 16.69% or $7.46. The stock’s beta now stands at 1.17 and when compared to its 200-day moving average and its 50-day moving average, HFC price stands -18.38% below and -2.76% below respectively. Its average daily volatility for this week is 2.14% which is less than the 2.45% recorded over the past month.

HollyFrontier Corporation (HFC) rose 4.68% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one year, the equity price has embarked on a rally that has seen it rise 13.05% and is now up by 2.03% since start of this year. A look at its monthly performance shows that the stock has recorded a -4.77% fall over the past 30 days. Its equity price dipped by -5.35% over the past three months which led to its overall six-month decrease to stand at -27.3%.

Experts from research firms are bullish about the near-term performance of HollyFrontier Corporation with most of them predicting a $63.36 price target on a short-term (12 months) basis. The average price target by the analysts will see a 21.47% rise in the stock and would lead to HFC’s market cap to surge to $11.05B. The stock has been rated an average 2.9, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 18 analysts that track HollyFrontier Corporation (NYSE:HFC) and find out that 11 of them rated it as a Hold. 4 of the 7 analysts rated it as a Buy or a Strong Buy while 3 advised investors to desist from buying the stock or sell it if they already possess it.

A look at HFC technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 47.92 point. Its trading volume has added 131547 shares compared to readings over the past three months as it recently exchanged 2311547 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 2180000 shares, and this is 1.06 times the normal volume.

The price of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) currently stands at $129.41 after it went down by $-3.19 or -2.41% and has found a strong support at $127.93 a share. If the SRPT price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $126.46 mark would also be bad for the stock as it means that the stock would plunge by 2.28% from its current position. However, if the stock price is able to trade above the resistance point around $132.25, then it could likely surge higher to try and break the upward resistance which stands at $135.1 a share. Its average daily volatility over the past one month stands at 4.18%. The stock has plunged by 0.09% from its 52-weeks high of $129.3 which it reached on Jun. 19, 2018. In general, it is 45.52% above its 52-weeks lowest point which stands at $70.5 and this setback was observed on Apr. 04, 2018.

Analysts have predicted a price target for Sarepta Therapeutics, Inc. (SRPT) for 1 year and it stands at an average $206.05/share. This means that it would likely increase by 59.22% from its current position. The current price of the stock has been moving between $129.3 and $133.62. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $169. On the other hand, one analyst is super bullish about the price, setting a target as high as $275.

The SRPT stock Stochastic Oscillator (%D) is at 18.59%, which means that it is currently oversold and its prices could jump very soon. The shares P/S ratio stands at 31.39 which compares to the 47.58 recorded by the industry or the 10.93 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 0, which is lower than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone down, with a quarterly decrease rate of -10.6% over the past five years.

Analysts view Sarepta Therapeutics, Inc. (NASDAQ:SRPT) as a Buy, with 1.7 consensus rating. Reuters surveyed 22 analysts that follow SRPT and found that 1 of those analysts rated the stock as a Hold. The remaining 21 were divided, with 21 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying Sarepta Therapeutics, Inc. (SRPT) shares or sell it if they already own it.

This post was originally published on *this site*